About Renetx Bio
Renetx Bio is a company based in New Haven (United States) founded in 2010 by Stephen Strittmatter. Renetx Bio has raised $13.42 million across 9 funding rounds from investors including HHS, Spring Mountain Capital and Connecticut Innovations. Renetx Bio operates in a competitive market with competitors including Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Edge Therapeutics and Ischemix, among others.
- Headquarter New Haven, United States
- Founders Stephen Strittmatter
- SectorsHealthcare
- Email••••••••
- Website renetx.com
- Social LinkedIn
- Total Equity Funding$13.42M (USD)
in 9 rounds
- Latest Funding Round$2.8M (USD), Series A
Sep 2020
- InvestorsHHS
& 3 more
Funding Insights of Renetx Bio
Renetx Bio has successfully raised a total of $13.42M across 9 strategic funding rounds. The most recent funding activity was a Series A round of $2.8 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.42M
- Total Rounds 9
- Last Round Series A — $2.8M
- First Round $3M
(Apr 2010)
- Investors Count 4
All 9 funding rounds of Renetx Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $2.8M | Series A | – | – | – |
| Sep 2020 | $3.09M | Grant | – | – | |
| Jul 2019 | $3.19M | Series A | – | – | – |
| May 2018 | – | Series A | – | Spring Mountain Capital, Connecticut Innovations | – |
| Dec 2017 | $425,000 | Series A | – | – | – |
| Jun 2017 | $7M | Series A | – | – | |
| Sep 2013 | $224,995 | Grant | – | – | |
| Apr 2010 | $3M | Grant | – | – | |
| Apr 2010 | $3M | Grant | – | – |
4 investors in total: 4 institutional.
Investors in Renetx Bio
Renetx Bio has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, Spring Mountain Capital and Connecticut Innovations.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital fund focused on multiple sectors | – | smcgrowthcapital.com | New York, United States | |
Venture capital services for biotech, IT, and innovative sectors in Connecticut. | – | ctinnovations.com | - | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | - | |
Donations are gathered to fund life-changing global projects. | – | wingsforlife.com | - |
Investor details for Renetx Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Renetx Bio
14 people are tracked at Renetx Bio (5 in leadership, 7 in board & advisors, 2 in team).
| Name | Role | Group |
|---|---|---|
Stephen Strittmatter | Founder | Leadership |
Erika Smith | CEO | Leadership |
George Maynard | President & CSO | Leadership |
Craig Hackett | VP, Process Science & Manufacturing | Leadership |
Crista Adamson | Director, Clinical Engagement | Leadership |
Gregory Ho | Director | Board & advisors |
Daniel P. Lammertse | Advisor | Board & advisors |
Sean Cassidy | Director | Board & advisors |
Andrew Blight | Advisor | Board & advisors |
Kevin Malobisky | Advisor | Board & advisors |
Steve Strittmatter | Founder & Scientific Advisor | Board & advisors |
David Wurzer | Director | Board & advisors |
Ann Hollmann | Office Manager | Team |
Emma McBurney | Board Observer | Team |
Complete people profiles for Renetx Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Renetx Bio
3 dated milestones of Renetx Bio across 10 years, from founding to its latest funding, stage changes and deals.
- Founded Renetx Bio is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Series A, of $2.8M.
Competitors of Renetx Bio
Renetx Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Tonix Pharma, Neuraptive, veriNOS pharmaceuticals, Edge Therapeutics and Ischemix, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tonixpharma.com | 2007 | New York, United States | $4.45M | 117 | Next-generation medicines for CNS and immunological disorders are developed. | |
| neuraptive.com | 2016 | Lafayette, United States | $12.5M | – | Therapeutic solution for the repair of cut and crushed peripheral nerves. | |
| verinos-pharma.com | 1998 | Wurzburg, Germany | $62.7M | – | Developer of therapeutics for retina and brain diseases | |
| edgetherapeutics.com | 2009 | New Providence, United States | $164.73M | 26 | Novel therapies for acute neurological conditions are developed and commercialized. | |
| ischemix.com | 2006 | Grafton, United States | $6.6M | – | Developer of cytoprotective therapy for traumatic brain injury | |
| proniras.com | 2018 | Seattle, United States | $11.23M | 2 | Small molecules are developed for seizures and brain injury treatment. | |
| neurexistherapeutics.com | 2020 | Aurora, United States | $605,000 | – | Neuroprotective therapeutic peptides are developed for brain disorder treatment. | |
| nervgen.com | 2016 | Vancouver, Canada | – | – | Nerve damage treatments are developed by inhibiting PTPσ receptor. |
Detailed competitors of Renetx Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Renetx Bio
Complete news archive for Renetx Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Renetx Bio
10 companies that operate in the same segment as Renetx Bio (Neurology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 | |
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
MR-interfaced ultrasound devices for cancer and neurology treatments are provided. | 1999 | Tirat Carmel, Haifa District, Israel | USD 574.2 M | – | – | |
AI-driven drug discovery platform for neurological diseases based on patients biomarkers | 2019 | San Francisco, California, United States | USD 144.72 M | – | 76 | |
Small molecule drugs for rare diseases are developed. | 1998 | South Plainfield, New Jersey, United States | USD 248.1 M | USD 1.73 B | 939 | |
Developer of small molecule therapeutics for endocrine and CNS disorders | 1992 | San Diego, California, United States | USD 10 M | USD 2.86 B | 1,800 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Renetx Bio
Renetx Bio was founded in 2010.
Renetx Bio is headquartered in New Haven, United States. It is registered at New Haven, Connecticut, United States.
Erika Smith is the current CEO of Renetx Bio.
Renetx Bio is a funded company, having raised a total of $13.42M across 9 funding rounds to date. The company's 1st funding round was a Grant of $3M, raised on Apr 2010.
ReNetx Bio (REstoration of neural NETworks) is engaged in the development of first in class therapeutics to treat injurydamage to the central nervous system (CNS). They are mainly targeted to treat conditions such as spinal cord injury (SCI), stroke, and glaucoma. The company was founded based on the technology (NogoTrap) developed by Dr. Stephen Strittmatters work at Yale University to improve neurologic function after CNS injury. The NogoTrap technology involves a decoy receptor called the Nogo Trap which binds to extracellular growth inhibitors of the CNS tissue (Nogo-A, MAG and OMgp). This technology as per company claims facilitates restoration across all facets of growth which include axonal regeneration (long distance), axonal sprouting (medium distance) and synaptic plasticity. The companys lead candidate targeting Spinal Cord Injury is currently under preclinical stage and is expected to start clinical trials by 2018.
Renetx Bio's top competitors include Tonix Pharma, Neuraptive and Neurexis Therapeutics.
Renetx Bio has 4 investors. Key investors include HHS, Spring Mountain Capital, Connecticut Innovations, and Wings for Life.